Fund moves

Johnson & Johnson (JNJ): Deprince Race & Zollo Inc reduced its stake -5,180 shares

Deprince Race & Zollo Inc reduced its stake in Johnson & Johnson, per its Q3 2025 13F.

258K
Shares reported · -5,180 vs prior quarter
0.96%
Disclosed portfolio weight
$47.8M
Reported value
Holdings as of
Sep 30, 2025
Filed
Oct 17, 2025

The story around this disclosure

Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.

  1. Mar 15, 2023CongressDisclosed purchase of JNJ — reported range $1,001 - $15,000
  2. Sep 26, 2024CongressDisclosed purchase of JNJ — reported range $1,001 - $15,000
  3. Oct 29, 2024CongressDisclosed purchase of JNJ — reported range $1,001 - $15,000
  4. Mar 19, 2025CongressDisclosed sale of JNJ — reported range $15,001 - $50,000
  5. Jul 31, 2025CongressDisclosed partial sale of JNJ — reported range $15,001 - $50,000
  6. Aug 4, 2025Congress · 1 personMembers of Congress: 2 purchases
  7. Aug 14, 2025CongressDisclosed partial sale of JNJ — reported range $1,001 - $15,000
  8. Aug 15, 2025InsiderCFO sold ~$2.98M of JNJ shares in the open market
  9. Aug 19, 2025CongressDisclosed partial sale of JNJ — reported range $1,001 - $15,000
  10. Aug 22, 2025InsiderCEO sold ~$22.5M of JNJ shares in the open market
  11. Sep 4, 2025Insider · 4 days before an 8-KOfficer sold ~$10M of JNJ shares in the open market
  12. Sep 8, 2025Company filing · Form 8-K · Executive changeChanged a top executive or board member“On September 8, 2025, Johnson & Johnson (the Company) announced that John Morikis was elected to the Board of Directors. The Board has determined that Mr. Morikis satisfies the applicable independence requirements of the NYSE Listed Company Manual.”
  13. Sep 23, 2025CongressDisclosed sale of JNJ — reported range $1,001 - $15,000
  14. Oct 9, 2025Federal contract · $19K obligatedDepartment of Veterans Affairs awarded Johnson & Johnson: $19K obligated to date
  15. Oct 10, 2025Congress · 1 personMembers of Congress: 2 sales
  16. Oct 14, 2025Company filing · Form 8-K · Results, Other newsReported its results, and reported other company news
  17. Oct 16, 2025Federal contract · $384K obligatedDepartment of Defense awarded Johnson & Johnson: $384K obligated to date
  18. Oct 17, 2025InsiderOfficer sold ~$4.19M of JNJ shares in the open market

What came next

  1. Oct 30, 2025Congress · 1 personMembers of Congress: 1 purchase, 1 sale
  2. Oct 31, 2025CongressDisclosed sale of JNJ — reported range $1,001 - $15,000
  3. Nov 5, 2025CongressDisclosed purchase of JNJ — reported range $1,001 - $15,000
  4. Nov 13, 2025CongressDisclosed partial sale of JNJ — reported range $1,001 - $15,000
  5. Nov 20, 2025CongressDisclosed partial sale of JNJ — reported range $15,001 - $50,000
  6. Nov 26, 2025Insider · Their first buy on recordDirector purchased ~$258K of JNJ shares in the open market
  7. Dec 4, 2025FDARecall: Impella 5.5 with SmartAssist¿ S2, Impella 5.5 with SmartAssist S2 Set, AU.
  8. Dec 9, 2025CongressDisclosed purchase of JNJ — reported range $1,001 - $15,000
  9. Dec 10, 2025Federal contract · $8K obligatedDepartment of Defense awarded Johnson & Johnson: $7.7K obligated to date
  10. Dec 12, 2025FDAFDA drug approval: Akeega
  11. Dec 15, 2025FDAFDA device approval: ETHIZIA
  12. Dec 17, 2025FDAFDA drug approval: Rybrevant Faspro
  13. Dec 17, 2025FDAFDA device clearance: ETHICON™ 4000 45mm Compact Stapler (EC3DT45C); ETHICON™ 4000 45mm Standard Stapler (EC3DT45S); ETHICON™ 4000 45mm Long Stapler (EC3DT45L); ETHICON™ 3D 45mm Whi…
  14. Dec 18, 2025CongressDisclosed sale of JNJ — reported range $1,001 - $15,000
  15. Dec 22, 2025FDAFDA device clearance: STRATAFIX™ Spiral PDS™ Plus Knotless Tissue Control Device; STRATAFIX™ Spiral MONOCRYL™ Plus Knotless Tissue Control Device
  16. Jan 9, 2026FDAFDA device clearance: ECHELON ENDOPATH Staple Line Reinforcement (ECH60R)
  17. Jan 18, 2026FDAFDA device clearance: CARTO™ 3 EP Navigation System V9.0 with PIU Plus
  18. Jan 21, 2026Company filing · Form 8-K · ResultsReported its results
  19. Jan 21, 2026FDARecall: MONARCH Platform, Bronchoscopy, Catalog Numbers: MON-000005-01 , MON-000005-01R , MON-000006 , MON-000006-RFB, MON-000008 with software
  20. Jan 26, 2026Insider · 1 personInsiders: 2 sales (~$22.1M)
View the official recordSEC Form 13F-HR

How to read SEC Form 13F-HR

Form 13F is the quarterly report in which investment managers that oversee $100 million or more list the US-listed stocks and some other securities they held on the last day of the quarter.

Full guide: What is an SEC Form 13F?

What else is on file for Johnson & Johnson

For Johnson & Johnson, OQRO holds 5 insider filings (SEC Form 4 or Form 144), 4 Congress trade reports, 4 fund holdings reports (13F) and 6 federal contract awards dated in the last 90 days.

These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its JNJ page.

How this filing works

Explore the data

Common questions

What does this filing report about Johnson & Johnson (JNJ) stock?

Deprince Race & Zollo Inc reduced its stake in Johnson & Johnson, per its Q3 2025 13F. Now 258K shares, $47.8M reported value, 0.96% of disclosed portfolio.

When did it happen, and when was it made public?

Holdings as of: Sep 30, 2025. Filed: Oct 17, 2025.

Is this a trade made on a known date?

No. A holdings report is a picture of the portfolio on the last day of the quarter. It shows what was held on that day, not the day or the price at which anything was bought or sold.

Where does this information come from?

From the SEC Form 13F-HR, a public record. The link to the official record is on this page, and OQRO copies its figures without changing them.

What else has been disclosed about Johnson & Johnson recently?

For Johnson & Johnson, OQRO holds 5 insider filings (SEC Form 4 or Form 144), 4 Congress trade reports, 4 fund holdings reports (13F) and 6 federal contract awards dated in the last 90 days. They are listed on the JNJ page.

Does this mean JNJ stock is a buy or a sell?

No. This page describes one public filing. A filing does not say why someone traded and is not a forecast, so OQRO gives no recommendation.

Is OQRO free?

Yes. Every page of OQRO is free with an account, which takes a minute with Google and needs no card. Only the AI assistant is paid.

Other disclosures at Johnson & Johnson

Everything OQRO holds on this company is on its JNJ page.

This is one filing. OQRO holds the rest

Insider trades filed with the SEC, stock trades disclosed by members of Congress, fund holdings from 13F filings and federal contract awards, each one in plain words next to its official filing. On this page it opens why the trade stands out, what the company did around that time, the price since, and every field of the form.

OQRO is free for everyone. No card, no trial

OQRO describes public disclosures and context calculated from them. It does not give personalized advice and does not recommend any transaction. How OQRO treats data